CardiaTec Biosciences, an AI drug target discovery company specialising in cardiovascular disease, has secured a £1.4 million pre-seed investment led by Laidlaw Scholars Ventures and APEX Ventures. Cardiovascular diseases have persisted as the world’s leading global cause of death since the 1980s. Yet, despite the rising number of deaths, cardiovascular investment and therapeutic innovation are … Continue reading Cambridge startup to combat cardiovascular diseases using AI